Competent Cells Market Snapshot
| Study Period: | 2018-2026 |
| Base Year: | 2021 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 9.4 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The competent cells market was estimated to be USD 1,625 million in 2020 and is expected to reach USD 2,790 million by the year 2026, at a CAGR of 9.4% over the forecast period.
The COVID-19 pandemic is exerting a significant effect on the competent cells market. Research and development activities have increased in the biotechnology field because of the pandemic. Cell cloning activities like recombinant protein expression and mutagenesis have seen increased focus since the COVID-19 pandemic due to which the market is witnessing robust growth. To better study the SARS-nCoV genome, there has been a huge demand for competent cells for making cloned copies of viral plasmids. For example, in May 2020, a paper was published in 'Cell Host & Microbe' which reported the construction of a full-length SARS-CoV-2 genome via in-vitro competent cells.
Advancements in molecular engineering due to the emergence of new cell technologies in biotechnology industries are augmenting the growth of the market studied. Additionally, increased investments from public and private companies and the introduction of novel product types are anticipated to boost the market growth in the studied regions. For example, Thermo Fisher, an American company, manufactures the ElectroMAX Stbl4 line of competent cells which can be used for high-efficiency cloning of unstable DNA, including repetitive DNA and retroviral sequences when genomic and cDNA library construction is done. It manufactures other products like MultiShot StripWell Mach1 T1 Phage-Resistant cells and ElectroMAX DH10B T1 Phage-Resistant cells which are both used for cloning purposes.
According to BIO Deutschland, in Germany, private biotechnology firms attracted around EUR 369 million in venture capital investment in 2018. Public biotechnology firms were also able to raise EUR 693 million from the stock market in 2018. Such high amounts of capital raising capabilities from major companies is likely to lead to further investment in research and development activities. This is expected to have a positive effect on market development.
However, the very high cost of research and development of competent cells and the market consolidation of a few major players are expected to hamper the market growth over the period.
Scope of the Report
Competent cells are E.coli cells in which their cell walls are altered so that they allow easy incorporation of foreign DNA into the cells. Cells are made competent by either chemical or electrical means. Competent cells are used in cell transformation, cell cloning, and other cell engineering applications. The competent cells market is segmented by type into chemically competent cells and electrocompetent cells. By application, the market is segmented into protein expression, cloning, biotechnology, and other applications. By end user, the market is segmented into biopharmaceutical companies, contract research organizations, and academic institutions. By geography, the market is segmented into North America, Asia-Pacific, Europe, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for all the above segments.
| By Type | |
| Chemically Competent | |
| Electrocompetent |
| By Application | |
| Protein Expression | |
| Cloning | |
| Biotechnology | |
| Other Applications |
| By End User | |
| Biopharmaceutical Companies | |
| Contract Research Organizations | |
| Academic Institutions |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Cloning Application Expected to Register Good Growth Rate Over the Forecast Period
Cloning, in the application segment, is projected to grow at significant rates owing to the high demand for molecular cloned products. COVID-19 has had a positive impact on the cloning industry as it has ushered in increased research and development investments by companies. Furthermore, the increase in research on cloning and financial support from various agencies are expected to boost the segment’s growth. Cell engineering techniques like somatic cell nuclear transfer (SCNT) have been shown to have a wide range of applications in generating transgenic animals, protecting endangered animals, and therapeutic cloning. These areas are likely to see renewed interest due to which demand for competent cells will increase, as they can be used in therapeutic cloning research.
The biotechnology segment is also projected to witness a notable growth rate due to increasing investments in R&D and commercialization of proteomics and genomic-based products. Furthermore, the need for advanced product technologies in the treatment of various diseases is projected to bolster the segment’s growth.
In addition, increased funding on studies for DNA cloning technologies in academic research institutions and use of these products in therapeutics are anticipated to strengthen the market growth in the near future.
To understand key trends, Download Sample Report
Asia-Pacific is Expected to show Good Growth over the Forecast Period
The Asia-Pacific market is anticipated to hold a majority share of the global competent cells market during the forecast period. The growth is attributed to extensive studies on DNA cloning technologies in the region and the presence of key market players. For example, in January 2021, Takara Bio Inc. announced the completion of its new facility called the Center for Gene and Cell Processing II for research and manufacturing purposes in Shiga, Japan.
Furthermore, continuous support from governments in advancing DNA technologies and growing demand for cloned products are expected to boost the market growth over the forecast period. For example, the Chinese Government has played a significant role in the development of biotechnology industries in the country. In June 2019, the China Bio-Industry Conference was held and was jointly sponsored by the Chinese Society of Bioengineering and the Guangdong Provincial Government. At the conference, the Guangzhou Nanshan Science and Technology Innovation Fund was launched as a public-private partnership with RMB 200 million in financing for biotech companies willing to do their research in the region. Initiatives such as these are expected to have a positive impact on the development of genetic engineering industries, which will further create a demand for competent cells. In addition, combining the artificial intelligence in developing the products and growing research and development on DNA technologies in research institutions are projected to bolster the market growth. Moreover, the need for advanced products for the treatment of diseases and favorable regulatory policies are supplementing the market growth.
Another company from the region, India based HiMedia Solutions manufactures many products for the competent cells market. Its four major products for the studied market are the Bacterial Transformation kit, HiPurA BL21(DE3) Competent Cells, HiPurA Competent Cells, and HiPurA XL1-Blue Competent Cells. The company is the premier manufacturer of competent cells in India. Some of its products, like the HiPurA Competent Cells, was the first chemically competent DH5a cells offered in the Indian market, which made cloning experiments easier. Presence of such companies is likely to have a positive effect on market development.
Moreover, the advent of innovative technologies in countries like South Korea, Japan, and Singapore, and the need for commercial cloning products for therapeutic uses are predicted to aid the market share over the forecast period. The Asia-Pacific region is anticipated to have a significant growth rate owing to the developing healthcare and research infrastructure, especially in emerging countries of the region.
To understand geography trends, Download Sample Report
Competitive Landscape
The competent cells market is moderately consolidated with a notable number of market players. Companies are focusing on developing new technologies in cell DNA cloning and broadening the applications of competent cells. The key market players operating in the market include Thermo Fisher Scientific, Merck KGaA, Qiagen, Takara Bio Inc., and New England BioLabs Inc.
Recent Developments
In January 2021, Agilent Technologies collaborated with CRISPR-assay maker Mammoth Biosciences to launch the latter's upcoming COVID-19 diagnostic test that can handle more than 4,000 samples per day.
In September 2020, Zymo Research, a major player in the market, announced that it has been granted CE IVD marks for three of its diagnostic products.
Table of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Commercial Demand and Continuous Support From Government and Educational Institutions
4.2.2 Advancements in Cell Technologies in Healthcare
4.3 Market Restraints
4.3.1 High Cost of Research and Development
4.3.2 Growing Market Consolidation and Difficult Market Entry
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type
5.1.1 Chemically Competent
5.1.2 Electrocompetent
5.2 By Application
5.2.1 Protein Expression
5.2.2 Cloning
5.2.3 Biotechnology
5.2.4 Other Applications
5.3 By End User
5.3.1 Biopharmaceutical Companies
5.3.2 Contract Research Organizations
5.3.3 Academic Institutions
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific
6.1.2 Merck KGaA
6.1.3 Agilent Technologies, Inc.
6.1.4 Takara Bio Inc.
6.1.5 New England Biolabs (UK) Ltd.
6.1.6 HiMedia Laboratories
6.1.7 Zymo Research
6.1.8 Avantor
6.1.9 TransGen Biotech Co., Ltd
6.1.10 Scarab Genomics
6.1.11 Lucigen Corporation
6.1.12 Genscript Corporation
6.1.13 Tonbo Biosciences
6.1.14 Enzynomics co Ltd
6.1.15 Klee GmbH
6.1.16 NZYTech, Lda
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Competent Cells Market market is studied from 2018 - 2026.
What is the growth rate of Global Competent Cells Market?
The Global Competent Cells Market is growing at a CAGR of 9.4% over the next 5 years.
Which region has highest growth rate in Global Competent Cells Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Competent Cells Market?
North America holds highest share in 2020.
Who are the key players in Global Competent Cells Market?
Thermo Fisher, Merck KGaA, New England Biolabs, Takara Bio, Agilent Technologies, Inc. are the major companies operating in Global Competent Cells Market.
